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Summary
Background Uncertainty remains concerning the association of blood cholesterol with the risk of subsequent 
dementia. Using data from people with lipid measurements in the UK Clinical Practice Research Datalink (CPRD), 
we examined the association between blood lipid levels and dementia (both vascular and non-vascular, including 
Alzheimer’s disease) by age at first measurement of blood lipids and duration of follow-up.
Methods We studied a cohort from the UK CPRD of people aged 40 years or older with a first total cholesterol 
recording between Jan 1, 1992, and Dec 31, 2009. Follow-up was until the first record of dementia, the last data 
collection date, patient death or transfer out of the practice, or Jan 5, 2015, whichever was earliest. We excluded 
individuals with a record of dementia before the total cholesterol measurement. We used Poisson regression to 
examine the association between baseline total cholesterol, LDL cholesterol and HDL cholesterol, and triglycerides 
and incident dementia diagnosis. Analyses were stratified by age at first measurement (<65 years or ≥65 years) and 
duration of follow-up (<10 years or ≥10 years). Our primary focus was LDL cholesterol. We adjusted for age, sex, 
calendar year, country within the UK, socioeconomic status, ethnicity, smoking, alcohol, body-mass index, 
comorbidities, and prescriptions.
Findings 1 853 954 people had a first total cholesterol recording (dementia diagnosis in 49 416 [2·7%] people), including 
953 635 [51·4%] people with LDL cholesterol values for analysis (dementia diagnosis in 21 602 [2·3%] people). Overall, 
we found a modest positive association between LDL cholesterol and dementia, with an adjusted rate ratio (RR) of 
1·05 (95% CI 1·03–1·06) per SD increase in LDL cholesterol (1·01 mmol/L or 39 mg/dL increase). Adjusted RRs 
per 1-SD increase in LDL cholesterol in people younger than 65 years at baseline (n=636 262) were 1·10 (95% 1·04–1·15) 
for dementia diagnosed in the first 10 years after measurement and 1·17 (1·08–1·27) for dementia diagnosed more 
than 10 years after measurement. Associations for LDL cholesterol in people aged 65 years or older at baseline 
(n=317 373) were weaker compared with people younger than 65 years (RR 1·03 [95% CI 1·01–1·05] for dementia 
diagnosed during the first 10 years of follow-up and 1·07 [1·03–1·13] for dementia diagnosed after 10 years). 
We observed a weaker association between total cholesterol and dementia incidence and no consistent associations 
for HDL cholesterol and triglycerides.
Interpretation LDL cholesterol measured in mid-life (<65 years) is modestly associated with dementia risk more than 
10 years later. LDL cholesterol should be added to the list of modifiable risk factors for dementia.
Funding The Alzheimer’s Society.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction 
According to the 2016 Global Burden of Disease study, 
the number of people with dementia was estimated to be 
43·8 million, more than doubling from 20·2 million 
in 1990.1 Prevention is particularly important to reduce 
the increasing global burden of dementia, since there is 
currently no cure for the disease. According to the Lancet 
Commission on Dementia Prevention, Intervention, and 
Care, 40% of dementia cases are attributable to so-called 
potentially modifiable risk factors, including lower 
levels of education, hypertension, obesity, hearing loss, 
smoking, depression, physical inactivity, social isolation, 
diabetes, alcohol consumption, traumatic brain injury, 
and air pollution.2 Notably, dyslipidaemia was not 
included in the list of potentially modifiable risk factors.
Evidence for the association between blood lipids (total 
cholesterol, LDL cholesterol, HDL cholesterol, and 
triglycerides) and the risk of dementia has been 
inconsistent. The association between total cholesterol 
and risk of dementia appears to vary with age at 
measurement (mid-life [<65 years] or later life [≥65 years]) 
and follow-up duration.3–8 Some studies reported no 
association or an inverse association with total cholesterol 
levels measured in later life, whereas those studies that 
showed a positive association examined the effect of mid-
life total cholesterol levels with longer follow-up. 
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However, synthesis of previous observational studies has 
been hampered by different study populations, different 
cutoff points of total cholesterol for categorisation, and 
varying methods for capturing dementia cases and 
controlling for confounding. There is even less 
information, and greater uncertainty, surrounding the 
association between LDL cholesterol, HDL cholesterol, 
and triglycerides and dementia risk.3–8 Therefore, a 
sufficiently large study that overcomes these variations 
might better determine if there is an association between 
blood cholesterols (total cholesterol, LDL cholesterol, and 
HDL cholesterol) and triglycerides and dementia risk by 
age at measurement and duration of follow-up.
Using data from people with lipid measurements in 
the UK Clinical Practice Research Datalink (CPRD), we 
examined the association between blood lipid levels and 
dementia incidence (both vascular and non-vascular) by 
age at first measurement of blood lipids (<65 years vs 
≥65 years) and duration of follow-up (<10 years vs 
≥10 years).
Our focus was LDL cholesterol, as this is a major 
component of total cholesterol. Analyses were  stratified, 
in keeping with other studies, by duration of follow-up, 
with a focus on 10 years or more since lipid measurement, 
to minimise reverse causality arising from a change in 
lipid levels during the prodromal phase of dementia, and 
age at first measurement of blood lipids, as people 
younger than 65 years are less prone to selection bias 
caused by the loss of older people who tend to die earlier.9
Methods 
Data source and participants
For this retrospective cohort study, we used data from the 
CPRD GOLD, a database of anonymised electronic 
health records collected from general practitioners (GPs) 
in the UK.10 As of Jan 5, 2015, more than 650 GPs have 
contributed data that met quality control standards to the 
CPRD, representing almost 7% of the UK population. 
The CPRD contains the following information: patient 
demographics, coded diagnoses (based on Read codes), 
prescriptions, laboratory test results, including total 
cholesterol, HDL cholesterol, and triglycerides, and 
referrals to secondary care. Dementia, among many 
other clinical diagnoses, has been validated in the CPRD, 
with a positive predictive value of over 80%.11,12
Participants were recruited from GPs satisfying the 
CPRD quality standards. Inclusion criteria included 
having at least 1 year of historical data, being aged 
40 years or older, and having at least one total cholesterol 
measurement between Jan 1, 1992, and Dec 31, 2009. 
Participants with a history of dementia were excluded. 
Participants with total cholesterol values <1·75 mmol/L 
Research in context
Evidence before this study
The association between dyslipidaemia and dementia has been 
much debated. We searched PubMed on Jan 5, 2020, using the 
search terms (“dementia” OR “cognitive decline”) AND (“lipid” 
OR “cholesterol” OR “triglycerides”), without restricting 
language or start and end dates of the search, and did manual 
searches of reference lists of previous studies. We identified 
several systematic and narrative reviews on this topic. Previous 
observational studies that examined the effect of midlife total 
cholesterol levels on dementia over longer follow-up durations 
were more likely to report a positive association than were 
studies measuring total cholesterol levels in later life and with 
shorter follow-up. However, these studies were small, with 
limited precision, and involved different study populations, 
methods to capture dementia, cutoff levels for total cholesterol, 
and methods to control for confounding. There are fewer and 
less conclusive data on the associations between LDL 
cholesterol and HDL cholesterol and triglycerides, and 
dementia.
Added value of this study
This study provides robust evidence of a positive association 
between risk of future dementia and LDL cholesterol measured 
at least 10 years before dementia diagnosis in people of middle 
age (<65 years). A weaker association between total cholesterol 
and dementia was found, suggesting that this association is 
largely driven by LDL cholesterol. We found no consistent 
evidence for an association between HDL cholesterol or 
triglycerides and dementia. As this is the largest single study to 
date to our knowledge, including a large number of participants 
with long-term follow-up to minimise reverse causation 
(ie, dementia causing changes in LDL cholesterol and total 
cholesterol levels during the preclinical period), our findings 
clarify the inconsistent results of previous smaller studies, 
particularly for LDL cholesterol.
Implications of all the available evidence
LDL cholesterol should be included in the list of so-called 
potentially modifiable risk factors (which also includes lower 
level of education, hypertension, obesity, hearing loss, 
smoking, depression, physical inactivity, social isolation, 
diabetes, alcohol consumption, traumatic brain injury, and air 
pollution, according to the 2020 Lancet Commission on 
Dementia Prevention, Intervention, and Care). Although 
randomised trials of statins have failed to show benefit in 
dementia incidence or cognitive dysfunction, such trials are 
limited by short duration of follow-up, few dementia events, 
and an inability to exclude such small risks. Middle age might 
be the best time to lower LDL cholesterol levels to reduce the 
risk of future dementia. Confirming this benefit might require 
follow-up beyond 10 years, with reliable measures to capture 
dementia, in large, randomised trials or comparative 
observational studies of interventions to lower LDL cholesterol.
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or >20 mmol/L were also excluded because of probable 
recording errors (figure 1).13
We identified people with measurements of HDL 
cholesterol and triglycerides on the day of the first total 
cholesterol recording. Among people with both 
measurements available, we estimated LDL cholesterol 
based on the Friedewald  formula.14  Participants with a 
triglyceride level of ≥4·52 mmol/L (because the 
Friedewald formula might not be valid14) and participants 
with unrealistic values of LDL cholesterol (<0·75 mmol/L 
or >8 mmol/L)13 were excluded.
This study uses data from the CPRD GOLD database 
obtained under licence from the UK Medicines and 
Healthcare products Regulatory Agency. However, the 
interpretation and conclusions contained in this report are 
those of the authors alone. This study was approved by the 
Medicines and Healthcare products Regulatory Agency’s 
Independent Scientific Advisory Committee (protocol 
number 15_148R). The protocol is available online.
Outcome and follow-up 
The primary outcome was the first diagnosis of dementia, 
based on diagnostic codes suggestive of dementia as 
recorded in CPRD (appendix pp 1–3).11,12 Patients were 
followed up from the date of their first total cholesterol 
measurement (referred to as the index date). Follow-up 
was until the first record of dementia, the general 
practice’s latest collection date of CPRD data, the end of 
the patient’s record collection (because of death or leaving 
the practice), or Jan 5, 2015, whichever occurred first.
Covariates 
We considered the following variables as potential 
confounding factors: age, sex, calendar year, country 
(England, Northern Ireland, Scotland, or Wales), practice-
level socioeconomic status, ethnicity (White, South Asian, 
Black, or mixed or other ethnicity), smoking and alcohol 
status, body-mass index (BMI), history of myocardial 
infarction, stroke, atrial fibrillation, heart failure, or 
chronic obstructive pulmonary disease (COPD), and 
prescriptions of anti-hypertensive, anti-diabetic, or lipid-
lowering drugs (statins, fibrates, nicotinic acids, or bile 
acid resins). Practice-level socioeconomic status was 
based on the postcodes of GPs and was assigned by 
quintiles according to the 2010 Office for National 
Statistics estimates of the Index of Multiple Deprivation. 
People with no record of ethnicity were grouped with 
White people, as was done in previous studies in UK 
primary care.15 Smoking and alcohol status and BMI were 
assigned using data recorded at the timepoint closest to 
the index date, using existing algorithms.16 We defined 
each comorbidity (myocardial infarction, stroke, atrial 
fibrillation, heart failure, and COPD) as being present if a 
relevant diagnostic code of that comorbidity was recorded 
at least once before a patient’s index date. Prescriptions of 
anti-hypertensive, anti-diabetic, and lipid-lowering drugs 
were defined in the year before the index date.
Statistical analysis 
We used Poisson regression to estimate incidence rates 
and rate ratios of dementia across categories of blood 
lipids. We first adjusted for age at risk (in 5-year bands, 
time-updated17) and sex, and then adjusted for additional 
covariates at baseline, namely calendar year (in 
5-year bands, time-updated17), country, practice-level 
socioeconomic status, ethnicity, smoking and alcohol 
status, BMI, comorbidities, and prescriptions. We 
adjusted for duration of follow-up using the log of the 
duration of follow-up as an offset variable. In fully 
adjusted models we used a complete case analysis as 
relatively few participants had missing data on 
smoking, alcohol, or BMI (<10% of the study 
participants). We reported rate ratio (RR) per 1-SD 
increase in each lipid fraction,18 and according to 
five categories commonly used for blood lipids.19
We investigated the associations stratified by age at 
first measurement (<65 years vs ≥65 years) and by 
duration of follow-up (<10 years vs ≥10 years). We first 
separated patients into two groups according to age at 




See Online for appendix
Figure 1: Flow chart of creation of the dataset for analysis from the entire CPRD
CPRD=Clinical Practice Research Datalink.
4 337 532 people aged ≥40 years registered in CPRD between 1992 and 2009
4 053 177 aged ≥40 years with ≥1 year of historical data in CPRD between 
1992 and 2009
1 988 567 aged ≥40 years with ≥1 total cholesterol measurement in CPRD 
between 1992 and 2009
1 869 347 aged ≥40 years with total cholesterol measurement after ≥1 year of 
historical data in CPRD
1 853 954 with total cholesterol measurement (entering the cohort on the 
day of first total cholesterol measurement after ≥1 year of historical 
data in CPRD between 1992 and 2009)
1 133 366 with HDL cholesterol measurement
1 201 656 with triglyceride measurement
953 635 with LDL cholesterol values (by the Friedewald formula)
284 355 registered in CPRD for <1 year
2 064 610 without total cholesterol measurement
119 220 with total cholesterol measurement only within <1 year of
the CPRD registration
15 393 excluded
3406 with unrealistic total cholesterol value
3333 <1·75 mmol/L
73 >20 mmol/L
11 987 with a previous diagnosis of dementia
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first lipid measurement in the CPRD (<65 years vs 
≥65 years). Within each age group, we divided each 
person’s follow-up period into the following two intervals: 
0–10 years since measurement and more than 10 years 
since measurement. Patients followed up for less than 
10 years only featured in the analysis of 0–10 years since 
measurement. Patients followed up for more than 
10 years featured in both analyses—their first 10 years of 
follow-up contributed to the analysis of 0–10 years and 
the remainder of their follow-up contributed to the more 
than 10 years analysis. A priori, we focused on people 
younger than 65 years at first measurement, who had 
long-term follow-up (≥10 years). Analyses of patients 
younger than 65 years are less prone to selection bias 
caused by loss to follow-up in older patients, who are 
often more frail and who tend to die earlier. Additionally, 
we focused on long-term associations to reduce reverse 
causality arising from a drop in lipid levels during the 
prodromal phase of dementia before a clinical diagnosis.20 
Although our population was based on the availability of 
total cholesterol recordings, our primary focus was LDL 
cholesterol. We also differentiated between vascular and 
non-vascular dementia diagnoses by considering patients 
to have vascular dementia if a vascular cause was 
suggested in the diagnostic codes.21 For vascular 
dementia, we censored patients who were diagnosed 
with non-vascular dementia on the day of diagnosis, and 
for non-vascular dementia, we censored patients 
diagnosed with vascular dementia. Further more, among 
patients with non-vascular dementia, we differentiated 
between Alzheimer’s disease and other or unspecified 
dementia (appendix pp 1–3).
We did several sensitivity analyses. First, we repeated 
analyses excluding users of lipid-lowering drugs at 
baseline, as we found substantial confounding due to lipid-
lowering drugs (mostly statins), which lower LDL 
cholesterol levels and were associated with higher levels of 
other conditions, such as smoking and recorded cardio-
vascular diseases. Second, we repeated analyses after using 
multiple imputation to account for missing data for 
smoking, alcohol, or BMI. Third, we used Cox regression 
models to confirm our results of Poisson regression 
models. Fourth, in the LDL cholesterol cohort, we included 
people with LDL cholesterol greater than 8 mmol/L, as this 
might indicate familial hypercholesterolaemia instead of 
an unrealistic value. Fifth, we did analyses stratified by sex 
and by timing of cohort entry (1992–2000 vs 2001–09) to 
examine potential effect modification by these factors. 
Sixth, we considered the role of the apolipoprotein E 
epsilon 4 (APOEε4) allele, which is associated with both 
increased LDL cholesterol and increased risk of dementia.2 
We used a simulation study to estimate the expected size 
of the association between LDL cholesterol and dementia 
that would be induced by the APOEε4 allele in the absence 
of any direct impact of LDL cholesterol on dementia risk 
(see appendix pp 35–36 for further details).
We used STATA (version 16) for statistical analyses.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
Between Jan 1, 1992, and Dec 31, 2009, 1 853 954 people 
with a first total cholesterol measurement were eligible 
for the study. We excluded 3406 people with first total 
cholesterol records less than 1·75 mmol/L (n=3333) and 
more than 20 mmol/L (n=73) due to being probable 
recording errors13 and 11 987 people with a history of 
dementia (figure 1).
Among the remaining 1 853 954 people with total 
cholesterol measurements, HDL cholesterol and 
triglycerides were available on the day of first total 
cholesterol recordings in 1 133 366 people and 
1 201 656 people, respectively, with 976 970 having both 
measurements available, enabling estimation of LDL 
cholesterol based on the Friedewald formula.14 After 
excluding 21 452 people with a triglyceride level of 
4·52 mmol/L or greater (because the Friedewald formula 
might not be valid14) and 1883 people with unrealistic 
values of LDL cholesterol (<0·75 mmol/L [n=1404] or 
>8 mmol/L [n=479]),13 953 635 people remained with LDL 
cholesterol values for analysis.
In the total cholesterol cohort, the median baseline age 
was 59 years (IQR 50–69), 905 830 (48·9%) of 1 853 954 
were male, and median follow-up was 7·4 years 
(IQR 4·6–10·4, maximum 23 years). The distribution of 
duration of follow-up by year of cohort entry is shown 
in the appendix (p 4). There were 49 416 (2·7%) 
diagnoses of dementia (including 13 564 vascular and 
35 852 non-vascular) at an overall incidence of 3·5 cases 
per 1000 person-years. Incidences by age, sex, and calendar 
year are shown in the appendix (p 5). Among patients who 
had a diagnosis of dementia, the mean age at diagnosis 
was 79·7 years (SD 7·7) in men and 82·1 years (7·5) in 
women. Mean levels of blood lipids were 5·62 mmol/L 
(SD 1·19) for total cholesterol, 3·42 mmol/L (1·01) for LDL 
cholesterol, and 1·45 mmol/L (0·42) for HDL cholesterol. 
The median level of triglycerides was 1·40 mmol/L 
(IQR 1·00–2·03).
Lower levels of LDL cholesterol were found more often 
in male participants, people with a greater number of 
comorbidities, and people prescribed lipid-lowering and 
anti-hypertensive drugs (table 1). Baseline characteristics 
by categories of total cholesterol, HDL cholesterol, and 
triglycerides are shown in the appendix (pp 6–11).
LDL cholesterol was not associated with increased 
dementia risk in age-adjusted and sex-adjusted models 
(RR per 1-SD higher LDL cholesterol levels 0·99, 95% CI 
0·97–1·00; table 2; figure 2). However, after adjustment 
for further potential confounders in fully adjusted 
models, higher levels of LDL cholesterol were associated 
with increased dementia risk (adjusted RR 1·05, 95% CI 
1·03–1·06).
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Overall (n=953 635) By LDL cholesterol category
<2·59 mmol/L or 
<100 mg/dL 
(n=199 037)
2·60–3·36 mmol/L or 
100–129 mg/dL 
(n=274 033)
3·37–4·14 mmol/L or 
130–159 mg/dL 
(n=262 589)
4·15–4·92 mmol/L or 
160–189 mg/dL 
(n=146 901)
>4·92 mmol/L or 
≥190 mg dL 
(n=71 075)
Age (years) 58 (49–68) 59 (48–71) 57 (48–68) 58 (49–67) 59 (50–68) 60 (52–68)
Sex
Male 458 953 (48·1%) 100 682 (50·6%) 133 359 (48·7%) 128 031 (48·8%) 68 165 (46·4%) 28 716 (40·4%)
Female 494 682 (51·9%) 98 355 (49·4%) 140 674 (51·3%) 134 558 (51·2%) 78 736 (53·6%) 42 359 (59·6%)













England 769 936 (80·7%) 155 960 (78·4%) 219 781 (80·2%) 213 821 (81·4%) 121 027 (82·4%) 59 347 (83·5%)
Northern Ireland 38 361 (4·0%) 8828 (4·4%) 11 893 (4·3%) 10 150 (3·9%) 5297 (3·6%) 2193 (3·1%)
Scotland 55 384 (5·8%) 12 833 (6·4%) 16 288 (5·9%) 14 888 (5·7%) 7779 (5·3%) 3596 (5·1%)
Wales 89 954 (9·4%) 21 416 (10·8%) 26 071 (9·5%) 23 730 (9·0%) 12 798 (8·7%) 5939 (8·4%)
Socioeconomic status (practice level)
1 (least deprived) 191 372 (20·1%) 38 073 (19·1%) 55 893 (20·4%) 53 671 (20·4%) 29 689 (20·2%) 14 046 (19·8%)
2 193 101 (20·2%) 40 141 (20·2%) 56 004 (20·4%) 53 384 (20·3%) 29 615 (20·2%) 13 957 (19·6%)
3 197 122 (20·7%) 40 505 (20·4%) 55 667 (20·3%) 54 621 (20·8%) 30 956 (21·1%) 15 373 (21·6%)
4 198 692 (20·8%) 43 187 (21·7%) 57 060 (20·8%) 53 753 (20·5%) 30 269 (20·6%) 14 423 (20·3%)
5 (most deprived) 173 348 (18·2%) 37 131 (18·7%) 49 409 (18·0%) 47 160 (18·0%) 26 372 (18·0%) 13 276 (18·7%)
Ethnicity
White or missing 925 120 (97·0%) 190 990 (96·0%) 264 857 (96·7%) 255 574 (97·3%) 143 715 (97·8%) 69 984 (98·5%)
South Asian 13 633 (1·4%) 4098 (2·1%) 4446 (1·6%) 3272 (1·2%) 1384 (0·9%) 433 (0·6%)
Black 8009 (0·8%) 2170 (1·1%) 2610 (1·0%) 1942 (0·7%) 953 (0·6%) 334 (0·5%)
Mixed or other 6873 (0·7%) 1779 (0·9%) 2120 (0·8%) 1801 (0·7%) 849 (0·6%) 324 (0·5%)
Smoking status
Non-smoker 426 707 (44·7%) 83 802 (42·1%) 125 230 (45·7%) 120 067 (45·7%) 66 260 (45·1%) 31,348 (44·1%)
Ex-smoker 337 394 (35·4%) 76 267 (38·3%) 95 947 (35·0%) 90 769 (34·6%) 50 529 (34·4%) 23 882 (33·6%)
Current smoker 185 854 (19·5%) 38 167 (19·2%) 51 774 (18·9%) 50 781 (19·3%) 29 551 (20·1%) 15 581 (21·9%)
Missing 3680 (0·4%) 801 (0·4%) 1082 (0·4%) 972 (0·4%) 561 (0·4%) 264 (0·4%)
Alcohol status
Non-drinker 115 187 (12·1%) 26 779 (13·5%) 32 649 (11·9%) 30 372 (11·6%) 16 955 (11·5%) 8432 (11·9%)
Ex-drinker 30,485 (3·2%) 7798 (3·9%) 8522 (3·1%) 7727 (2·9%) 4251 (2·9%) 2187 (3·1%)
Current drinker 752 172 (78·9%) 152 900 (76·8%) 216 615 (79·0%) 209 127 (79·6%) 117 197 (79·8%) 56 333 (79·3%)
Missing 55 791 (5·9%) 11 560 (5·8%) 16 247 (5·9%) 15 363 (5·9%) 8498 (5·8%) 4123 (5·8%)
Body-mass index (kg/m²)
<18 32 564 (3·4%) 10 245 (5·1%) 10 267 (3·7%) 7417 (2·8%) 3241 (2·2%) 1394 (2·0%)
18–25 260 460 (27·3%) 58 133 (29·2%) 76 866 (28·0%) 69 526 (26·5%) 37 519 (25·5%) 18 416 (25·9%)
>25–30 356 022 (37·3%) 67 462 (33·9%) 98 931 (36·1%) 100 738 (38·4%) 59 233 (40·3%) 29 658 (41·7%)
>30 254 017 (26·6%) 52 305 (26·3%) 73 342 (26·8%) 71 086 (27·1%) 39 280 (26·7%) 18 004 (25·3%)
Missing 50 572 (5·3%) 10 892 (5·5%) 14 627 (5·3%) 13 822 (5·3%) 7628 (5·2%) 3603 (5·1%)
Medical history
Myocardial infarction 37 317 (3·9%) 18 475 (9·3%) 9258 (3·4%) 5605 (2·1%) 2634 (1·8%) 1345 (1·9%)
Stroke 35 476 (3·7%) 13 664 (6·9%) 9400 (3·4%) 7059 (2·7%) 3614 (2·5%) 1739 (2·4%)
Heart failure 17 128 (1·8%) 6765 (3·4%) 4753 (1·7%) 3277 (1·2%) 1605 (1·1%) 728 (1·0%)
Atrial fibrillation 34 674 (3·6%) 11 885 (6·0%) 10 195 (3·7%) 7535 (2·8%) 3575 (2·4%) 1484 (2·1%)
Chronic obstructive 
pulmonary disease
29 034 (3·0%) 8702 (4·4%) 8318 (3·0%) 6975 (2·7%) 3498 (2·4%) 1541 (2·2%)
Anti-hypertensives 328,599 (34·5%) 90 974 (45·7%) 91 552 (33·4%) 80 793 (30·8%) 44 275 (30·1%) 21 005 (29·6%)
Anti-diabetics 78 730 (8·3%) 31 400 (15·8%) 22 236 (8·1%) 15 204 (5·8%) 6981 (4·8%) 2909 (4·1%)
Lipid-lowering drugs* 123 320 (12·9%) 69 197 (34·8%) 31 300 (11·4%) 13 887 (5·3%) 5791 (3·9%) 3145 (4·4%)
Data are median (IQR) or n (%). *Among lipid-lowering drug users, 97·0% were on statins, and others were on fibrates, nicotinic acids, or bile acid resins.
Table 1: Baseline characteristics of patients with LDL cholesterol values overall and by category
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Associations between blood lipid levels and dementia 
varied depending on age at first measurement and 
duration of follow-up (table 2; figure 3). The fully adjusted 
RRs per 1-SD increase in LDL cholesterol (1·01 mmol/L 
or 39 mg/dL increase) in people younger than 65 years at 
baseline (n=636 262) were 1·10 (95% CI 1·04–1·15) for 
dementia diagnosed in the first 10 years after 
measurement and 1·17 (1·08–1·27) for dementia 
diagnosed more than 10 years after measurement. 
Associations for LDL cholesterol in people 65 years or 
older at baseline (n=317 373) were weaker compared with 
people younger than 65 years (1·03 [1·01–1·05] for 
dementia diagnosed during the first 10 years of follow-up 
and 1·07 [1·03–1·13] after 10 years). In people with LDL 
cholesterol measurement who were younger than 
65 years and had follow-up for 10 or more years, according 
to the commonly used five categories of LDL cholesterol 
(<2·59 mmol/L, 2·60–3·36 mmol/L, 3·37–4·14 mmol/L, 
4·15–4·92 mmol/L, and >4·92 mmol/L [<100 mg/dL, 
100–129 mg/dL, 130–159 mg/dL, 160–189 mg/dL, and 
≥190 mg/dL]), the fully adjusted RR comparing the 
highest and the lowest category was 1·59 (95% CI 
1·13–2·22; figure 3).
Overall, associations of LDL cholesterol with vascular or 
non-vascular dementia were similar (fully adjusted RRs 
per 1-SD increase were 1·03 (95% CI 1·00–1·06) and 1·05 
(95% CI 1·04–1·07), respectively; appendix p 12). However, 
in analyses that further separated non-vascular dementia, 
the adjusted RRs were 1·11 (1·08–1·14) for Alzheimer’s 
disease and 1·01 (0·99–1·04) for other or unspecified 
dementia (appendix p 13). In people with LDL cholesterol 
measurement aged younger than 65 years and with 
follow-up for 10 or more years, the adjusted RRs were 1·30 
(1·14–1·48) for Alzheimer’s disease and 1·13 (0·98–1·30) 
for other or unspecified dementia.
The association between total cholesterol and dementia 
was weaker than the association for LDL cholesterol but 
followed a similar pattern (fully adjusted RR per 1-SD 
increase 1·02, 95% CI 1·01–1·03), with the strongest 
association observed in people younger than 65 years with 
more than 10 years after first total cholesterol measurement 
(1·08, 95% CI 1·03–1·12; appendix pp 14–16). For HDL 
cholesterol, the fully adjusted RR per 1-SD increase 
was 1·00 (0·98–1·01), with no associations irrespective of 
age or duration of follow-up (appendix pp 14, 17–18). For 
triglycerides, we found some suggestion of a U-shaped 
association (appendix p 19), but the overall association was 
weak (adjusted RR per 1-SD increase 0·97, 95% CI 
0·96–0·99), as were all associations irrespective of age 
and duration of follow-up (appendix pp 14, 20).
In sensitivity analyses, findings were similar after 
exclusion of lipid-lowering drug users at baseline 
(appendix pp 21–29), using imputation to include 
patients with missing data at baseline (appendix p 30), 
using Cox regression models (appendix p 31), or 
including people with LDL cholesterol greater than 
8 mmol/L (appendix p 32). The association between LDL 
cholesterol and dementia was similar in men and women 
(appendix p 33), and in people who entered the cohort 
in 1992–2000 versus 2001–09 (appendix p 34). In a 
simulation study for the APOEε4 allele, we estimated 
that in the absence of any causal relationship between 
Figure 2: RRs for dementia diagnosis by categories of LDL cholesterol 
(n=953 635)
RR=rate ratio. BMI=body-mass index. *Predefined covariates included age at risk 
(in 5-year bands, time-updated), sex, calendar year (in 5-year bands, time-
updated), country, practice-level socioeconomic status, ethnicity, smoking and 
alcohol status, BMI, history of myocardial infarction, stroke, atrial fibrillation, 
heart failure, or chronic obstructive pulmonary disease, and prescriptions of 
anti-hypertensive, anti-diabetic, or lipid-lowering drugs at baseline. As a 
complete case analysis, we excluded patients with missing data on smoking, 






















LDL cholesterol category, mmol/L (mg/dL)
Age and sex adjusted
Fully adjusted*
Overall (n=953 635) People with first measurement at 
age <65 years (n=636 262)
People with first measurement at 
age ≥65 years (n=317 373)
Follow-up <10 years 
(n=636 262)
Follow-up ≥10 years 
(n=147 393)
Follow-up <10 years 
(n=317 373)
Follow-up ≥10 years 
(n=62 249)
Number of outcomes, n 21 062 1686 577 17 372 1967
Age and sex adjusted RR (95% CI) 0·99 (0·97–1·00) 1·00 (0·95–1·04) 1·11 (1·03–1·21) 0·97 (0·96–0·99) 1·04 (0·99–1·08)
Fully adjusted RR (95% CI)* 1·05 (1·03–1·06) 1·10 (1·04–1·15) 1·17 (1·08–1·27) 1·03 (1·01–1·05) 1·07 (1·03–1·13)
Data are adjusted RRs (95% CI) per SD increase of LDL cholesterol, unless otherwise indicated. SD in the overall population (n=953 635) was 1·01 mmol/L for LDL cholesterol. 
BMI=body-mass index. RR=rate ratio. *Adjusted for age at risk (in 5-year bands, time-updated), sex, calendar year (in 5-year bands, time-updated), country, practice-level 
socioeconomic status, ethnicity, smoking and alcohol status, BMI, history of myocardial infarction, stroke, atrial fibrillation, heart failure, and chronic obstructive pulmonary 
disease, and prescriptions of anti-hypertensive, anti-diabetic, and lipid-lowering drugs at baseline. As a complete case analysis, we excluded patients with missing data on 
smoking, alcohol, or BMI (accounting for <10% of the study participants).
Table 2: RRs per SD increase of LDL cholesterol for dementia diagnosis by age at measurement and follow-up length
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LDL cholesterol and dementia risk, confounding by the 
APOEε4 allele would induce a RR for dementia of 1·09 
per 1-SD increase in LDL cholesterol (appendix pp 35-36). 
Therefore, confounding caused by the APOEε4 allele is 
unlikely to entirely explain the observed relationship 
between LDL cholesterol and dementia risk in people 
younger than 65 years with 10 or more years of follow-up.
Discussion 
In this cohort study, with over 1·8 million people 
with total cholesterol measurements and almost 
1 million people with LDL cholesterol measurements 
followed up over more than two decades, we observed 
modest positive associations between total cholesterol 
and LDL cholesterol and dementia risk. These associations 
were not fully explained by age, sex, and available baseline 
covariates. The associations were stronger for total 
cholesterol and LDL cholesterol measurements in 
mid-life (<65 years) and with longer follow-up (≥10 years). 
The association was stronger for LDL cholesterol than for 
total cholesterol, suggesting that the association between 
total cholesterol and dementia is in part driven by LDL 
cholesterol. There was almost no association between 
HDL cholesterol or triglycerides and dementia. Mid-life 
lipid levels are more likely to reflect individuals’ exposure 
to dyslipidaemia over their life course, compared with 
late-life lipid levels, as lipid levels might fall in later life.20 
This bias is expected to be less pronounced in our 
analyses of patients younger than 65 years by excluding 
diagnoses in the first 10 years of follow-up.
Our findings are consistent with previous small studies 
that aimed to minimise the effect of reverse causation by 
including sufficient events after 10 years of follow-up, 
such as the Three Cities cohort (n=9294), which showed a 
significant association between total cholesterol and LDL 
cholesterol and dementia when using a 13-year,18 but not a 
7-year, follow-up.22 Our findings suggest that short-term 
follow-up after lipid measurement, or measurement in 
later life, might result in an absent or inverse association 
between total cholesterol or LDL cholesterol and dementia. 
Unlike many previous studies, we also explored by 
simulation how the APOEε4 allele can affect associations 
between dementia and LDL cholesterol, finding that it 
could not entirely explain the association observed in our 
study. In our study, the relationship between either HDL 
cholesterol or triglycerides and dementia was weak, with 
narrow CIs, suggesting an absence of any clinically 
meaningful association between these lipids and dementia 
risk. A 2021 Danish study found that people with the top 
1% of triglyceride concentrations had a higher risk of 
Figure 3: RRs for dementia diagnosis by categories of LDL cholesterol according to age at measurement and follow-up duration
RR=rate ratio. BMI=body-mass index. *Predefined covariates included age at risk (in 5-year bands, time-updated), sex, calendar year (in 5-year bands, time-updated), 
country, practice-level socioeconomic status, ethnicity, smoking and alcohol status, BMI, history of myocardial infarction, stroke, atrial fibrillation, heart failure, or 
chronic obstructive pulmonary disease, and prescriptions of anti-hypertensive, anti-diabetic, or lipid-lowering drugs at baseline. As a complete case analysis, we 
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non-Alzheimer’s related dementia,23 but that more 
modestly elevated (51st to 99th percentiles) triglyceride 
levels were not significantly associated with either 
Alzheimer’s dementia or non-Alzheimer’s dementia.
The mechanism of how, over a prolonged period starting 
in mid-life, LDL cholesterol might cause Alzheimer’s 
disease (the major dementia subtype) remains speculative.24 
Lipids in the brain might influence the function of cleavage 
enzymes such as β-secretase and γ-secretase, resulting in 
insoluble Aβ protein production, leading to Alzheimer’s 
disease. Several genes, such as APOE, have important 
roles in brain cholesterol transport and are associated with 
Alzheimer’s disease. As the blood–brain barrier prevents 
direct transport of lipids between plasma and the CNS, 
plasma levels might not reflect lipid levels in the brain over 
a short period of time; longer periods might be required 
for dementia to become clinically evident. The role of LDL 
cholesterol in cerebrovascular disease and vascular 
dementia remains uncertain.
Our study has several strengths. To our knowledge, this 
is the largest study to date of the association between 
blood lipids and dementia, with over 1·8 million people 
with total cholesterol and nearly 1 million people with 
LDL cholesterol followed up for up to 23 years. This 
statistical power allows precise risks of dementia to be 
investigated by categories of age at first measurement 
(<65 years and ≥65 years) and follow-up duration 
(<10 years and ≥10 years). Although the prodromal period 
of dementia might be longer than that of other diseases, 
we reduced reverse causality bias (ie, the onset of 
dementia leading to lower LDL cholesterol and total 
cholesterol levels20) by analysing cases over 10 years after 
the initial lipid measurement. Our results are not 
explained by confounding from available covariates 
including age, sex, BMI, smoking, several comorbidities, 
and lipid-lowering and anti-hypertensive agents.
However, our study has several limitations. Selection 
bias might exist, as lipid measurements were not taken 
routinely until 2009 for all individuals aged 40–74 years 
without a previous diagnosis of cardiovascular disease or 
risk factors.25 We found that among 4 million people 
registered for at least 1 year in the CPRD between 1992 
and 2009, only approximately half had undergone total 
cholesterol measurements (figure 1). Therefore, our 
estimated associations might not be representative of the 
general UK population if the association between total 
cholesterol and LDL cholesterol and dementia are 
different in patients not selected into our cohort. An 
association between LDL cholesterol and all-cause 
mortality could also cause selection bias, since many 
patients only enter the cohort when they are older. 
However, we expect any such bias to be modest, as LDL 
cholesterol is only weakly associated with all-cause 
mortality.26,27 A further issue is the definition and 
classification of dementia. Dementia diagnosis in the 
CPRD has a positive predictive value of over 80%,11,12 but a 
sensitivity of around 50%,28 which might have changed 
over time. However, non-differential underdiagnosis of 
dementia would not change the association we found. 
The use of primary care records for the timing and 
diagnosis of dementia is more accurate and unbiased 
than using death certificates or hospital admissions 
because, in the UK, dementia is usually diagnosed first in 
primary care or at hospital outpatient clinics. Contact 
with GPs (and other physicians) might occur more often 
in people with higher LDL cholesterol levels, potentially 
leading to increased reporting of dementia, which might 
inflate the excess risk in those with high LDL cholesterol 
levels. Additionally, mild cognitive impairment was not 
examined in the current study, since it might not be 
accurately recorded by non-specialist primary physicians 
in the CPRD. Although we adjusted for many known risk 
factors for dementia,2 we cannot exclude the possibility of 
unmeasured confounding factors. We could not obtain 
information on educational background, but adjusted for 
practice-level socioeconomic status, which is correlated 
with education. Although we adjusted for baseline use of 
lipid-lowering drugs and did sensitivity analyses 
excluding users of lipid-lowering drugs at baseline, we 
did not have data on dosing or compliance with statin use 
during follow-up. We investigated the role of the APOEε4 
allele via a simulation study but could not precisely adjust 
for this because genetic information was not available for 
our study population. We assessed associations of LDL 
cholesterol and total cholesterol measured at a single 
timepoint with dementia risk, which are weaker than 
associations for long-term average levels of these risk 
factors because of regression dilution bias.29 Furthermore, 
random variations among different laboratories in the 
measurements of blood lipids could dilute the association 
between lipid levels and dementia diagnosis (meaning 
that the true association might be even larger).
Blood lipids are modifiable by lifestyle changes or lipid-
lowering drugs. Randomised trials have found no evidence 
that statins prevent cognitive decline or dementia, but 
such trials are severely limited by the duration of follow-up 
(<5 years).30 There is some evidence from randomised 
trials and comparative non-randomised studies that statins 
in younger people, those in earlier stages of dementia, and 
those with the APOEε4 allele might modify cognitive 
function,31–33 which could translate to a meaningful benefit 
at the population level for an irreversible disease that is a 
major cause of disability and mortality worldwide. The 
data to support an association between LDL cholesterol 
levels and dementia are as strong as the evidence for the 
association between blood pressure, which is on the list of 
modifiable risk factors for dementia, and dementia.2
In conclusion, LDL cholesterol levels in mid-life 
(<65 years) are modestly associated with dementia risk 
after at least 10 years of follow-up. LDL cholesterol should 
be added to the list of modifiable risk factors for dementia.
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